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underwent drug-eluting stent implantation from 4 hospitals in China
were enrolled. All of them were with high on-treatment platelet
reactivity (HPR), which was deﬁned as adenosine diphosphate
induced platelet aggregation (by light transmission aggregometry)
>65%. All of them were treated with aspirin. Patients were random-
ized by the ratio of 1:3:3 to: Group A, clopidogrel 75 mg/d for one year
(n¼50) ; Group B, clopidogrel 150mg/d for 30 days followed by 75mg/
d until one year (n¼150); or Group C, policosanol 40mg/d for 6 month
and clopidgrel 75mg/d for one year (n¼150). The primary endpoints
was the reversion rate of HPR at one-month (reversion was deﬁned as
platelet aggregation <65%). The secondary endpoints were 12-month
major adverse cardiac events (MACE), which included cardiac death,
non-fatal myocardial infarction or ischemic symptoms driven target
vessel revascularization.
RESULTS At 30 days, the reversion rate of HPR were 34.0%, 55.2% and
48.7% in Group A, group B and group C, respectively (P¼0.029). MACE
occurred in 4 (8.0%), 6(4.0%) and 5(3.3%) patients (P¼0.342). There
was 1 (0.7%) major bleeding and 1 (0.7%) minor bleeding event in high
maintenance dose clopidogrel group, no major or moderate bleeding
in the other two groups. The minimal bleeding in Group B was
signiﬁcantly higher than Group C (10.7% vs 2.7%, P¼0.022).
CONCLUSIONS Policosanol reduced platelet reactivity to a similar
extent as high maintenance dose of clopidogrel without increasing
bleeding rate.
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BACKGROUND Female patients are at higher risk of contrast-induced
acute kidney injury (CIAKI) compared to males. In the multicenter,
prospective, TRACK-D study, short-term rosuvastatin has proven
effectively reduce CIAKI in patients with type 2 diabetes mellitus and
stage 2-3 chronic kidney disease (CKD). This study aimed to explore
the efﬁcacy of rosuvastatin in the female TRACK-D population.
METHODS This study was a gender-based analysis of 2998 patients
(1044 females) enrolled in the TRACK-D study and were randomized
to short-term (2 days before and 3 days after procedure) rosuvastatin
therapy or standard of care. The primary outcome was the incidence
of CIAKI and the secondary outcome was a composite of death, dial-
ysis/hemoﬁltration or worsening heart failure at 30 days.
RESULTS CIAKI incidence was comparable between male and female
patients in the overall study population (2.5% vs. 3.4%, p¼0.165) and
in the rosuvastatin group (2.4% vs. 2.1%, P¼0.72), while it was higher
for females in the control group (3.1% vs. 5.3%, P¼0.04). Female was
an independent risk factor of CIAKI (Odds ratio: 1.65, 95% conﬁdence
interval: 1.03-2.63, p¼0.036). Rosuvastatin treatment vs. control
lowered CIAKI rate in females (2.1% vs. 5.3%, relative risk ¼0.39, 95%
conﬁdence interval: 0.19-0.77, number needed to treat [NNT]¼31),
particularly among those with CKD stage 2 (1.2% vs. 4.1%, p¼0.011).
Secondary outcome incidence was similar for females in the rosu-
vastatin and control groups (3.7% vs. 4.9%, p¼0.37).
CONCLUSIONS Compared to males, untreated females with diabetes
mellitus and CKD had a higher risk of CIAKI, which can be reduced by
short-term rosuvastatin treatment.
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infarction undergoing primary percutaneous coronary intervention via
radial access: a subgroup analysis from the BRIGHT trial
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BACKGROUND Emerging evidence suggested a superiority of biva-
lirudin compared with heparin or heparin plus GPI, however,primarily restricted in patients undergoing transfemoral primary
percutaneous coronary intervention (PCI) and suffering relative
higher access site bleeding. This trial aimed to explore the safety and
efﬁcacay of bivairudin in patients underwent primary PCI via radial
access.
METHODS In the BRIGHT trial, a total of 2194 AMI patients
with planned emergency PCI were enrolled and randomized to
receive bivalirudin, heparin or heparin plus tiroﬁban. The present
study was a prespeciﬁed subgroup analysis of the BRIGHT trial that
compared 30-day outcomes in patients with radial access (n¼1723)
among bivalirudin (n¼576), heparin alone (n¼576) and heparin plus
tiroﬁban (n¼571) arms. The primary outcome was 30-day net
adverse clinical event (NACE), deﬁned as a composite of major
cardiac and cerebral events (MACCE, including all-cause death, re-
infarction, ischemia-driven target vessel revascularization or stroke)
or any bleeding.
RESULTS Among patients of radial access, the primary outcome of 30-
day NACE occurred in 5.7% with bivalirudin, 7.8% with heparin alone
(vs bivalirudin, P¼0.159), and 10.3% with heparin plus tifoﬁban (vs
bivalirudin, P¼0.004). The 30-day bleeding rate was 0.9% for biva-
lirudin, 2.3% for heparin, and 5.8% for heparin plus tiroﬁban
(P<0.001). The rates of MACCE (4.9% vs 5.7% vs 4.6%, P¼0.899), stent
thrombosis (0.5% vs 0.5% vs 0.7%, P¼0.899) and acquired thrombo-
cytopenia (0.2% vs 0.5% vs 0.9%, P¼0.257) at 30 days were similar
among three arms.
CONCLUSIONS In patients with radial access, bivalirudin kept supe-
rior over heparin plus tiroﬁban on reducing 30-day NACE, primarily
due to the decrease in bleeding events. Although with no statistical
signiﬁcance, bivalirudin brought improvement on the primary
outcome compared with heparin monotherapy.
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BACKGROUND Female patients are at higher risk of both bleeding
and ischemic events during percutaneous coronary interventions
(PCI). The aim of the present study was to evaluated the safety and
efﬁcacy of bivalirudin during emergency PCI in female patient with
acute myocardial infarction (AMI).
METHODS Study population was derived from the BRIGHT trial, a
multi-center, randomized, active drug-controlled clinical trial. A
total of 392 female patients were enrolled in the BRIGHT trial,
including 127 patients randomized to the bivalirudin group and 265
patients randomized to the control group (heparin with or without
tiroﬁban). The primary efﬁciency endpoint was 30-day net adverse
clinical event (NACE), deﬁned as all-cause death, re-infarction,
ischemia-driven target vessel revascularization, stroke or any
bleeding. The second efﬁciency endpoints was 30-day major cardiac
and cerebral events (MACCE), deﬁned as all-cause death, re-
infarction, ischemia-driven target vessel revascularization and
stroke.
RESULTS The incidence of 30-day NACE (6.3% vs. 21.5%, p＜
0.001), any bleeding (2.4% vs. 12.8%, p¼0.001) and BARC 2-5 type
bleeding (1.6% vs. 7.2%, p¼0.021) in the bivalirudin group were lower
than that in the control-group. The incidence of MACCE （3.4% vs.
9.4%, p¼0.55) and stent thrombosis（0% vs. 1.1%, p¼0.229） were
comparable between the two groups. Multivariate COX analysis
showed that, bivalirudin (odds ratio [OR]:0.245, 95% conﬁdence in-
terval [CI]: 0.113-0.532, p< 0.001), transradial access (OR: 0.119, 95%
CI: 0.067-0.211, p＜0.001), and statin (OR: 0.254 , 95%CI: 0.08-0.807,
p¼0.02) were independent protective factors for 30-day NACE in fe-
male patients.
CONCLUSIONS The risk of bleeding and the incidence of 30-day
adverse events were higher in female patients compared to male
patients. In this high risk patient cohort, compared to heparin with
or without tiroﬁban, use of bivalirudin during the perioperative
period of emergency PCI signiﬁcantly reduces the incidence of
bleeding with similar anticoagulation effects.
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BACKGROUND Suboptimal platelet inhibition still represents an impor-
tant challenge, especially for patients undergoing percutaneous coronary
interventions (PCI). Chronic kidney disease (CKD) is a common comor-
bidity of patients with coronary artery disease, and may potentially inﬂu-
ence platelet reactivity. So far only few studies have assessed the role of
CKD on response to dual antiplatelet therapy with conﬂicting results.
Therefore, the aim of our study was to evaluate the impact of CKD on
platelet function in patients treated with dual antiplatelet therapy (DAPT)
after a recent acute coronary syndrome or PCI.
METHODS Patients treated with DAPT (ASA + clopidogrel or tica-
grelor) for an ACS or elective patients undergoing PCI were scheduled
for platelet function assessment at 30-90 days post-discharge. Platelet
function was assessed by whole blood impedance aggregometry
(Multiplate- Roche Diagnostics AG), HRPR was considered for ASPI
test >862 AU*min (for ASA) and ADP test values >417 AU*min (for
ADP-antagonists). Chronic renal failure was deﬁned as an estimated
glomerular ﬁltration rate of 60 ml/min/1.73m2 or less, calculated by
applying MDRD (Modiﬁcation of Diet in renal Disease) formula.
RESULTS Our population included a total of 537 patients of which 308
(57.3%) received ASA and clopidogrel and 229 (42.6%) received ASA
and ticagrelor. Patients with renal failure at baseline (101 out of 537,
18.8%) were older, with higher prevalence of history of hypertension,
myocardial infarction and coronary artery bypass graft surgery.
Moreover, they had a lower ejection fraction at baseline and were
more often in therapy with diuretics, but less often with statins at
admission. They had lower haemoglobin and higher glycated hae-
moglobin. HRPR was observed in 1.5% of patients treated with ASA
with no difference according to renal function (p ¼ 0.18). HRPR for
ADP-antagonists was observed in 23.7% of patients, with no difference
according to renal function (p ¼ 0.50). This result was conﬁrmed both
with clopidogrel (31.9% versus 38%, p ¼ 0.41) and ticagrelor (13.1%
versus 10.8%, p ¼ 0.99), also after correction for all baseline con-
founders (clopidogrel: adjusted OR [95%CI] ¼ 1.26 [0.60 - 2.63], p ¼
0.54) (ticagrelor: adjusted OR[95%CI] ¼ 0.95 [0.54 - 1.65], p ¼ 0.84).
The absence of association between renal function and platelet reac-
tivity was conﬁrmed at linear regression analysis both with clopi-
dogrel (r ¼ -0.04, p ¼ 0.52) and ticagrelor (r ¼ 0.006, p ¼ 0.92).
CONCLUSIONS In patients receiving dual antiplatelet therapy,
chronic renal failure did not inﬂuence ADP-mediated platelet reac-
tivity, with both ticagrelor or clopidogrel. No inﬂuence of chronic
renal failure was found on the effectiveness of ASA.
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BACKGROUND Platelet Inhibition and Patient Outcomes Trial (PLATO
trial) demonstrated that aspirin and ticagrelor were superior to aspirin
and clopidogrel in reducing thrombotic complications. Continuous
infusion of IIb/IIIa inhibitors (GPI) was used in 40% of patients with
ticagrelor in the PLATO trial. However, the inhibition of platelet ac-
tivity with ticagrelor starts rapidly and it is questionable whether
continuous infusion of GPI with ticagrelor is needed, We, therefore,
compared the impact of GPI bolus only vs. bolus and short infusion
of GPI with ticagrelor on percent inhibition of platelet aggregation
(%IPA) and outcome in patients with non-ST-segment myocardial
infarction (NSTEMI).METHODS A total of 70 patients with NSTEMI were randomized to
ticagrelor 190 mg loading and eptiﬁbatide bolus-only (TEP) vs. tica-
grelor loading and eptiﬁbatide bolus plus 2 h infusion(TEPI) admin-
istrated before stenting. Light transmission aggregometry was
performed and %IPA was calculated at baseline, 2 h, 6 h, and 24 h
using ADP, TRAP, collagen, and arachidonic acid (AA). Cardiac en-
zymes, hemoglobin and hematocrit were measured at baseline and 24
h. The event rates were determined at 30-day follow-up.
RESULTS In patients randomized to TEP vs. TEPI, there were no
signiﬁcant difference in the %IPA values at 2 h and 6 h with ADP 5mM
(100%  0.01 vs. 99%  0.25 and 99%  2.4 vs. 99%  1.2, respectively)
and with ADP 20 mM (Fig. 1), as well as with collagen. However, %IPA
was lower at 24 h (still >60) compared with that at 2 h and 6 h. Percent
IPA with TRAP 10 or 20 mM was higher at 6 h in patients randomized to
TEPI vs. TEP (87%  13 vs. 74%  17; P<0.01, respectively).This had no
bearing on outcomes since ADP was highly inhibited by ticagrelor at 6
h. There were no signiﬁcant differences in troponin or hemoglobin
levels among the groups. During follow-up, there was no stent
thrombosis or myocardial infarction.
CONCLUSIONS Percent IPA values with ADP and collagen were not
signiﬁcantly different comparing ticagrelor with eptiﬁbatide bolus
only vs. ticagrelor and eptiﬁbatide bolus plus 2 h infusion. Eptiﬁbatide
bolus only highly inhibited platelets aggregation while allowing
bridging to the antiplatelet effect of ticagrelor and circumventing the
need for continuous eptiﬁbatide infusion. There was no signiﬁcant
difference in bleeding or MI between the 2 groups.
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BACKGROUND Uninterrupted warfarin with intra-procedural heparin
is a commonly used anticoagulation strategy during atrial ﬁbrillation
